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A B S T R A C T   
Osteocytes, the most abundant bone cell type, are derived from osteoblasts through a process in which they are 
embedded in an osteoid. We previously showed that nutrient restriction promotes the osteocyte transcriptional 
program and is associated with increased mitochondrial biogenesis. Here, we show that increased mitochondrial 
biogenesis increase reactive oxygen species (ROS) levels and consequently, NRF2 activity during osteocyto-
genesis. NRF2 activity promotes osteocyte-specific expression of Dmp1, Mepe, and Sost in IDG-SW3 cells, primary 
osteocytes, and osteoblasts, and in murine models with Nfe2l2 deficiency in osteocytes or osteoblasts. Moreover, 
ablation of Nfe2l2 in osteocytes or osteoblasts generates osteopenia and increases osteoclast numbers with 
marked sexual dimorphism. Finally, treatment with dimethyl fumarate prevented the deleterious effects of 
ovariectomy in trabecular bone masses of mice and restored osteocytic gene expression. Altogether, we un-
covered the role of NRF2 activity in osteocytes during the regulation of osteocyte gene expression and main-
tenance of bone homeostasis.   
1. Introduction 
Bone is a dynamic tissue that undergoes continuous remodeling to 
adapt to the physiological demands of the whole organism. Of the major 
bone cell types, osteocytes make up more than 90% of the total bone 
cells. Presently, it has become clear that osteocytes communicate to 
osteoblasts and osteoclasts to coordinate bone remodeling, acting as 
physical mechanosensors and secreting endocrine regulators [1–3]. 
Lower osteocyte activity has been directly linked to bone fragility, 
osteopenia associated with aging or diabetes, chronic kidney disease, 
and atherosclerosis [1,4,5]. 
Osteocytes are derived from osteoblasts through an active process in 
which they are embedded in an osteoid matrix. During osteocytogenesis, 
dramatic morphological changes occur with the acquisition of a unique 
gene expression profile [6]. During osteocytogenesis, the progressive 
expression of osteocyte-specific genes can be identified. Dmp1 and Mepe 
are markers of osteocyte specification, whereas Fgf23 and Sost are 
indicative of mature osteocytes [7]. However, the exact mechanisms 
that govern the transition from osteoblasts into osteocytes, as well as 
how osteocytes exert regulatory functions are not completely defined. 
One of the driving forces of osteoblast-osteocyte transition is likely to be 
their encasement within a mineralized bone matrix. The 
lacuno-canalicular system connects osteocytes and allows those near the 
surface to interact with bone lining cells and vasculature [8]. None-
theless, the mechanisms of diffusion between the bone surface and os-
teocytes are challenged to maintain an adequate supply and exchange of 
oxygen, nutrients, and metabolic products [9–11]. We recently 
demonstrated that restriction of the glucose supply promotes the oste-
ocyte transcriptional program and is associated with increased mito-
chondrial biogenesis [12]. Since mitochondria are the main source of 
reactive oxygen species (ROS), it is likely that increased electron 
transport chain activity will also result in increased ROS production 
during osteocytogenesis. It has been shown that controlled ROS pro-
duction contributes to cell specification of osteoclasts, whereas exces-
sive ROS production is detrimental for osteoblastogenesis and bone 
homeostasis [13–15]. 
Controlled ROS generation is the net effect of a balance between ROS 
generation and its clearance by cellular antioxidant systems. Upon 
sensing endogenous or exogenous oxidative stress, the major inducible 
system to maintain redox homeostasis is NRF2-KEAP1 signaling. 
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Nuclear factor (erythroid-derived 2)-like2 (Nfe2l2, NRF2) is a member of 
a family of basic leucine zipper transcription factors that binds to anti-
oxidant response elements (AREs) in the regulatory regions of genes 
encoding detoxifying enzymes and antioxidant proteins [16]. 
NRF2-KEAP1 is a two-component system that controls NRF2 nuclear 
levels in the cytoplasm Kelch-like ECH-associated protein 1 (KEAP1), 
which forms a ubiquitin E3 ligase complex with cullin3 (CUL3) and 
polyubiquitinates and promotes NRF2 degradation. Increased oxidati-
ve/electrophilic stress directly modifies key cysteine residues in KEAP1, 
reduces ubiquitination and results in stabilization of NRF2. Accumu-
lated nascent NRF2 can then translocate to the nucleus, heterodimerize 
with sMAF, and activate transcription. The role of NRF2-KEAP1 in bone 
homeostasis may depend on factors, such as age, sex, or high vs. low 
activation levels [17,18]. Some studies revealed that deletion of Nfe2l2 
in female mice resulted in a deficit in postnatal bone acquisition and 
increased bone loss [17,19]. However, similar Nfe2l2-deletion ap-
proaches in male mice led to controversial results. Some studies reported 
increased bone acquisition and mass [17,20], whereas others showed 
reduced bone density, load-driven bone formation, and increased 
radiation-induced bone loss [21,22]. Similarly, moderate NRF2 activa-
tion by heterozygous deletion of Keap1 led to sexual dimorphic results 
with higher bone mass in male but not female mice [18]. A limitation of 
these previous studies was that genetic modifications of Nfe2l2 in mice 
affected all cell types and tissues. Therefore, we cannot exclude the in-
fluence of paracrine and endocrine factors; studies with cell-type specific 
knockout mice of NRF2 would provide more insight into their specific 
role in bone biology and pathophysiology. 
In this study, we addressed the specific role of NRF2 in osteocytes 
and osteoblasts in vivo. We report that increased mitochondrial 
biogenesis increased ROS levels and NRF2 activity during osteocyto-
genesis. NRF2 activity promoted osteocytic specification through tran-
scriptional activation of osteocyte-specific genes. Furthermore, 
conditional ablation of Nfe2l2 in osteocytes or osteoblasts induces 
osteopenia and increases the number of osteoclasts with marked sexual 
dimorphism. Finally, our results showed that treatment with the NRF2 
activator dimethyl fumarate (DMF) prevents the deleterious effects of 
ovariectomy in trabecular bone mass of mice and restored osteocytic 
gene expression suggesting that might be beneficial for osteopenic bone 
pathologies. 
2. Materials and methods 
2.1. Cell cultures 
IDG-SW3 cells were obtained from Dr. L. Bonewald and cultured as 
previously described by Ref. [7]. Briefly, IDG-SW3 were maintained and 
expanded in proliferative conditions (33 ◦C in αMEM with 5 mM 
glucose, 10% FBS, 2 mM glutamine, 1 mM pyruvate, 100 U/ml peni-
cillin, 0.1 mg/ml streptomycin, and 50 U/ml IFN-γ) on type I 
collagen-coated plates. To induce osteogenesis, cells were seeded on 
type I collagen-coated plates and cultured in osteogenic media (37 ◦C in 
αMEM with 10% FBS, 2 mM glutamine, 1 mM pyruvate, 100 U/ml 
penicillin, and 0.1 mg/ml streptomycin with 50 μg/ml ascorbic acid and 
4 mM β-glycerophosphate, in the absence of IFN-γ). 
Primary osteocytes were isolated with a protocol derived from Nij-
weide et al. [23]. Briefly, mice limbs (tibiae, femurs, and humeri) and 
calvariae from 5 mice were pooled, cut, and serially digested on a 
rotating shaker at 37 ◦C. Bone pieces were incubated in a collagenase 
solution [trypsin (0.025%)/collagenase II (1 mg/ml) in α-MEM] for 25 
min. The solution was discarded and the bone pieces were washed in 
PBS. This was repeated two more times, for a total of three digestions 
(digestions 1 to 3). Then, bone pieces were incubated with EDTA solu-
tion (5 mM EDTA in PBS containing 1% BSA, pH = 7.4) for 25 min. The 
solution was discarded (digestion 4), and the bone pieces were washed 
in PBS (digestion 4). Bone pieces were incubated with collagenase so-
lution for 25 min, the solution was kept for osteoblast isolation, and the 
bone pieces were washed in PBS (digestion 5). Bone pieces were incu-
bated with EDTA solution for 25 min, the solution was kept for osteo-
blast isolation (digestion 6), and the bone pieces were washed in PBS. 
Digestion 5 and 6 were combined and spun down at 200×g for 5 min. 
The cell pellet was resuspended in osteogenic media (αMEM with 10% 
FBS, 2 mM glutamine, 1 mM pyruvate, 100 U/ml penicillin, and 0.1 
mg/ml streptomycin with 50 μg/ml ascorbic acid and 4 mM β-glycer-
ophosphate). Bone pieces were incubated with collagenase solution for 
25 min, the solution was kept for cell plating, and the bone pieces were 
washed in PBS (digestion 7). Bone pieces were incubated with EDTA 
solution for 25 min, the solution was kept for cell plating, and the bone 
pieces were washed in PBS (digestion 8). Bone pieces were incubated 
with collagenase solution for 25 min, the solution was kept for cell 
plating (digestion 9). Digestions 7 to 9 were combined and spun down at 
200×g for 5 min. The cell pellet was resuspended in α-MEM culture 
media and plated on type-I rat tail collagen coated culture plates. Os-
teocytes were cultured in α-MEM supplemented with 5% FBS, 5% calf 
serum, 1 mM pyruvate, 100 U/ml penicillin, and 0.1 mg/ml strepto-
mycin. Osteoblasts and osteocytes were maintained at 37 ◦C and 5% 
CO2 in a humidified incubator for up to 7 days. 
2.2. Animal models 
To delete Nfe2l2 specifically in osteocytes, mice carrying loxP se-
quences flanking exon 5 of Nfe2l2 gene (SN25433 from The Jackson 
Laboratory) were crossed with Dmp1-cre/ERT2 transgenic line D77 
(SN029594 from The Jackson Laboratory) that expressed tamoxifen- 
inducible Cre recombinase (cre/ERT2) under the control of the mouse 
dentin matrix protein 1 (DMP1) promoter to generate Nfe2l2; Dmp1-cre/ 
ERT2 mice. Heterozygous Dmp1-cre/ERT2 mice with floxed Nfe2l2 
(Nfe2l2f/f) were crossed with Nfe2l2f/f to obtain experimental (Nfe2l2f/f; 
Dmp1-Cre/Ert2) and control (Nfe2l2f/f) mice. The resulting Nfe2l2f/f; 
Dmp1-cre/ERT2 mice were fertile and born at the anticipated Mendelian 
ratio. To induce recombination of floxed Nfe2l2 alleles, 3-week-old 
Nfe2l2f/f (WT) and Nfe2l2f/f; Dmp1-Cre/Ert2 (KO) mice received a total 
of 5 intraperitoneal injections of 20 mg/kg tamoxifen free base (Sigma) 
with 48h in between. Tamoxifen powder was dissolved in ethanol at a 
concentration of 100 mg/ml and suspended in corn oil at a concentra-
tion of 20 mg/ml by shaking for 1 h at 37 ◦C. Eight-week-old mice were 
euthanized and samples were collected for μCT and gene expression 
analysis. 
Osteoblast-specific Nfe2l2-deficient mice (Nfe2l2;Col1a1-Cre) were 
generated by crossing heterozygous Col1a1-Cre mice (Tg(Col1a1-cre) 
1Kry [24] with Nfe2l2 floxed mice, which was described previously. 
Nfe2l2f/f;Col1a1-Cre (KO) mice were fertile and born at the Mendelian 
ratio. Eight-week-old mice were euthanized and samples were collected 
for μCT and gene expression analysis. 
To analyze the effect of dimethyl fumarate in osteoporosis, 8-week- 
old female mice underwent a bilateral ovariectomy (OVX) and an 
equal number of mice underwent SHAM surgery (SHAM). OVX and 
SHAM were randomly divided into DMF (animals treated with 100 mg/ 
kg of DMF) or vehicle treatment groups. For the treatment, DMF was 
suspended in 0.8% methylcellulose and sonicated until it was 
completely dissolved. The DMF or vehicle was given daily by oral 
gavage for 8 weeks, starting 72 h after surgery. Mice were euthanized 24 
h after the last administration and samples were collected for μCT and 
gene expression analysis. 
All animals had ad libitum access to food (Teklad, 2014: Harlan- 
Teklad, Indianapolis, IN, USA) and water. Mice were maintained at 
22–24 ◦C on a 12-h light/12-h dark cycle. All procedures were approved 
by the Ethics Committee for Animal Experimentation of the Generalitat 
of Catalunya. 
2.3. Retroviral transduction 
Retroviral pMSCV-NRF2 (generated from pcDNA4-NRF2 from 
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Addgene) and the pMSCV-GFP control virus were used for NRF2 over-
expression in primary osteocytes. After infection, cells were cultured for 
five days in osteogenic media. Retroviral pMSCV-puro-Cre-ERT2, 
pMSCV-puro, and pMSCV-GFP virus were used for Nfe2l2 deletion as-
says in primary osteoblasts and osteocytes from Nfe2l2 f/f mice. Puro-
mycin (5 μg/ml) was used for the selection of infected cells. Tamoxifen 
(1 μM) was added at 48 h for the activation of Cre recombinase. Cells 
were lysate at least 24 h after the last tamoxifen administration. 
2.4. Fluorescence confocal imaging 
IDG-SW3 and primary osteoblasts and osteocytes were stained with 
250 nM Mitotracker-Deep-red (ThermoFisher), 5 μM CellROX Deep Red 
(Invitrogen) for 30 min or 2 μM MitoSOX Red (Invitrogen) for 15 min at 
37 ◦C. Cells were examined in a Zeiss LSM 880 laser scanning confocal 
spectral microscope equipped with an incubation control system (37 ◦C, 
5% CO2). Images corresponding to single confocal sections were taken 
using a 63x oil immersion objective lens. Images were analyzed using 
Zeiss software. 
2.5. Flow cytometry 
IDG-SW3 and osteoblasts were stained with Mitotracker Deep Red 
(ThermoFisher), CellROX Deep Red (ThermoFisher) or MitoSOX Red 
(Invitrogen). Then, cells were rinsed twice with PBS. Cells were incu-
bated with 0.25% Trypsin and 0.02% EDTA at 37 ◦C for 5–10 min until 
cells became rounded and started to detach. Cell suspensions were 
collected and centrifuged at 150xg for 5 min. Cell pellets were rinsed 
three times with PBS and resuspended in PBS. Before flow cytometry 
analysis, cell suspensions were filtered with a 0.70 μm nylon mesh to 
remove aggregates. Cell viability was assessed with 7-ADD. Results were 
analyzed with BD FACSDiva™ Software. 
2.6. Intact cell respirometry 
Mitochondrial function of intact cells was measured by high- 
resolution respirometry (Oxygraph-2k, Oroboros Instruments). IDG- 
SW3 cells were cultured in differentiation media with the indicated 
times. Cells were trypsined and resuspended again in differentiation 
media without FBS. 700,000 cells were added to the experimental 
chamber. Following stabilization of routine respiration, ATP synthesis 
was inhibited with 1 μg/ml of oligomycin to analyze respiratory 
uncoupling. Next, carbonylcyanide-4-(trifluoromethoxy)-phenyl- 
hydrazone 1 μM (FCCP) was titrated to achieve maximum flux 
through the electron transfer system (ETS). Finally, respiration was 
inhibited by the sequential addition of rotenone (0.1 μM) and antimycin 
A (2.5 μM). The remaining O2 flux after inhibition with antimycin A (O2 
flux independent of the electron transfer system) was subtracted to 
calculate the different respiratory states. Oxygen flux values were 
expressed relative to protein content determined by the BCA method. 
2.7. Gene expression 
Total RNA was isolated from IDG-SW3, primary osteoblasts, primary 
osteocytes, and mouse calvaria cells using the TRIsure reagent (Bioline, 
London, UK). Purified RNA was reverse-transcribed using the High- 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA, USA). Quantitative PCR was carried out using the ABI Prism 
7900 HT Fast Real-Time PCR System and a Taqman 5′-nuclease probe 
method (Applied Biosystems) with SensiFAST Probe Hi-ROX Mix (Bio-
line). All transcripts were normalized to TATA binding protein (Tbp) 
expression. 
2.8. Western blot assay 
Identification of proteins from cell extracts was performed by 
immunoblotting against NRF2 (Cell Signaling #12721), KEAP1 (Santa 
Cruz Biotechnology #514914), OXPHOS complexes (Mitosciences 
#607300), or α-TUBULIN (Millipore #CP06), diluted at 1:1000. 
Immuno-reactive bands were detected with horseradish-peroxidase- 
conjugated secondary antibodies and an EZ-ECL kit (Biological In-
dustries, Cromwell, CT, USA). 
2.9. Chromatin immunoprecipitation assay 
A ChIP assay was performed as previously described [25]. Primary 
osteocytes were treated with 5 μM DMF for 48 h. Cells were fixed with 
1% formaldehyde for 10 min. ChIP was carried out using 1 μg of 
anti-NRF2 (Cell Signaling #12721) or anti-IgG (Upstate) and purified 
with 20 μl Magna ChIP Protein A + G Magnetic Beads (Millipore). Pu-
rified DNA fragments were analyzed by qPCR with SYBR Green. 
2.10. Determination of mtDNA by qPCR 
Two μg of total DNA was used for mitochondrial DNA determination 
by qPCR. Primers for a mitochondrial DNA gene (tRNA-Glu) and a nu-
clear DNA gene (Fgf23) were used. The cycling conditions used were 43 
cycles of 30 s at 95 ◦C, 30 s at 70 ◦C, and 60 s at 72 ◦C. 
2.11. Mitochondrial isolation 
Mitochondria were isolated as described by Ref. [26]. Briefly, cells 
were trypsinizate and centrifuged at 300xg for 5 min. Cell pellet was 
resuspended in 1 ml MIB Buffer (200 mM sucrose, 10 mM TRIS/MOPS, 1 
mM EGTA/Tris, pH 7.4). Cell suspension was homogenized using a glass 
potter on ice. Homogenate was centrifuged at 600xg at 4 ◦C for 10 min to 
remove cell debris. Supernatant was collected and mitochondria were 
pellet by centrifugation at 1,0000xg, 4 ◦C for 10–15 min. Pellet was 
washed once with MIB buffer. The final pellet was resuspended in MIB 
buffer or the appropriate buffer for each assay. 
2.12. Determination of cellular GSSG and GSH 
The GSSG/GSH ratio was determined as described by Senft et al. 
[27]. Briefly, 2 × 105 cells were lysed with 600 μl of ice-cold PCA-RQB 
buffer [20 mM HCl, 5 mM diethylenetriaminepentaacetic acid (DTPA)], 
10 mM ascorbic acid, and 6% perchloric acid. Samples were centrifuged 
at 12,000g for 5 min at 4 ◦C. Supernatants were collected for GSSG/GSH 
ratio determination while the pellet was kept for protein quantification 
and normalization. The acidic pH of deproteinized samples was 
neutralized with 1 mM phosphate buffer at pH 7. For the determination 
of GSH, 45 μl of neutralized sample was incubated with 2 μl of RQB 
buffer (20 mM HCl, 5 mM DTPA, 10 mM ascorbic acid) or NEM (7.5 mM 
N-ethylmaleimide in RQB buffer) for 5 min at room temperature. Then, 
100 μl of 0.1 M phosphate buffer and 15 μl of O-PA (5 mg of ortho-ph-
thaldialdehyde in ethanol) were added to each tube. The reaction was 
incubated for 30 min at room temperature in the dark. Samples were 
loaded in a black 96-well Costar plate with a flat clear bottom. Fluo-
rescence was measured in a FLUOstar plate (excitation 365 ± 5 nm, 
emission 430 ± 20 nm) and GSH concentration was calculated relative 
to a GSH standard curve. For the determination of GSSG, 45 μl of 
neutralized sample were incubated with 2 μl NEM (7.5 mM N-ethyl-
maleimide in RQB buffer) for 5 min at room temperature. Then, 3 μl of 
RQB buffer or 100 mM Na2S2O3 were added to each tube. The reaction 
was incubated for 1 h at room temperature in the dark. Then, 100 μl of 
0.1 M phosphate buffer and 15 μl of O-PA (5 mg of ortho-ph-
thaldialdehyde in ethanol) were added to each tube. The reaction was 
incubated for 30 min at room temperature in the dark. Samples were 
loaded in a black 96-well Costar plate with a flat clear bottom. Fluo-
rescence was measure in a FLUOstar plate (excitation 365 nm, emission 
430 nm) and GSSG concentration was calculated relative to a GSH 
standard curve. 
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2.13. Determination of mitochondrial GSSG and GSH 
Mitochondrial glutathione levels were determined using the Quan-
tification kit for oxidized and reduced glutathione (Sigma-Aldrich) 
based on the 5,5′-dithio-bis(2-nitro-benzoic acid; DTNB) assay. Briefly, 
Mitochondria were isolated as described previously. Mitochondrial 
pellets were resuspended in 10 mM HCl, and lysed by freezing and 
thawingtwice. 5-Sulfosalicylic acid was added to a final concentration of 
0.5%. GSSG and GSH were determined following manufacture in-
structions. Color changes were monitored by absorbance at 405 nm. 
GSH and GSSG levels were quantified using standard curves. 
2.14. Hydrogen peroxidase assay 
The generation of Mitochondrial H2O2 was determined using 
Amplex™ Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermofisher) 
following manufacturer’s instructions. Briefly, mitochondria were iso-
lated as described previously. Mitochondrial pellets were diluted in 1x 
Reaction Buffer and incubated in presence of 100 μM Amplex® Red 
reagent and 0.2 U/mL HRP for 30 min at room temperature and pro-
tected from light. Fluorescence was measured in a fluorimeter (Ex: 550 
nm/Em: 590 nm). H2O2 levels were quantified using a standard curve. 
2.15. MicroCT analysis 
Femurs from mice were dissected, cleaned of soft tissue, and fixed in 
4% paraformaldehyde (PFA) for 24 h. High-resolution images from the 
femur were acquired using a microCT imaging system (Skyscan 1272, 
Bruker microCT, Kontich, Belgium) in accordance with recommenda-
tions from the American Society of Bone and Mineral Research 
(ASBMR). Samples were scanned in air at 60 kV and 166 μA with an 
exposure time of 5600 ms, using a 1 mm aluminum filter and an 
isotropic voxel size of 11 μm. Two-dimensional images were obtained 
every 1◦ of a 180◦ rotation and subsequently reconstructed using NRe-
con reconstruction software and analyzed with CT-Analyzer (SkyScan). 
For trabecular measurements, manual VOI was employed, starting at 
100 slices from the distal growth plate of the femur and extending to the 
diaphysis for 150 slices. Cortical measurements were performed by 
delineating the femur medial cortex for 100 slices around the femoral 
midshaft. A Gaussian noise filter was applied for reconstruction and a 
global binary threshold was manually established at 15 for trabecular 
analysis and at 50 for cortical analysis. 
2.16. Histological analysis 
For histological preparations, samples were fixed in 4% para-
formaldehyde for 24 h at 4 ◦C, decalcified in 14% EDTA (pH 7.4) for 6 
weeks, and embedded in paraffin. Samples were cut into 7 μm sections 
and stained with Hematoxylin/Eosin or TRAP. 
2.17. Statistical analysis 
Statistical analyses were performed using Student’s t-test or two-way 
analysis of variance (ANOVA). Quantitative data are presented as the 
mean ± standard error of the mean (SEM). Differences were considered 
significant at *p < 0.05, **p < 0.01, and ***p < 0.001. 
3. Results 
3.1. Increased OXPHOS activity and ROS generation are associated with 
osteocytogenesis 
Confluent IDG-SW3 cells differentiated into osteocytes after 14–21 
days in culture, constituting a well-established model of osteocyto-
genesis [7]. Previous reports from our group suggested metabolic 
reprogramming towards oxidative phosphorylation during osteocyte 
differentiation [12]. Therefore, using this cell model, we investigated 
the mitochondrial content during osteocyte specification. Measurement 
of mitochondrial DNA (mtDNA) revealed that differentiation resulted in 
a progressive increase in the number of mitochondria per cell (Fig. 1A). 
This increase in mtDNA was consistent with increased protein levels of 
different oxidative phosphorylation (OXPHOS) complexes and higher 
signal of the mitochondrial membrane potential probe MitoTracker, 
suggesting that the newly formed mitochondria were metabolically 
active (Fig. 1B and C). Moreover, we also measured mitochondrial 
respiration in intact, differentiated IDG-SW3 cells. We determined 
routine O2 consumption, leak state (uncoupled respiration after addition 
of oligomycin), electron transfer capacity (after FCCP addition, (ETS)). 
Differences in respiratory parameters were not significant between 
groups although slightly increased electron transfer capacity was 
observed in cells differentiated for 14 days (Suppl. Figure 1A). To 
determine whether osteocytic differentiation also resulted in altered 
ROS levels, we used confocal microscopy and FACS analysis to assess 
oxidative stress in these cells. Enhanced levels of ROS measured by 
CellRox were observed in parallel with higher mitochondrial content 
during osteocytogenesis in intact IDG-SW3 cells (Fig. 1D and E and 
Suppl. Figure 1B). Determination of mitochondrial peroxides by Mito-
SOX and AmplexRed in isolated mitochondria from differentiated 
IDG-SW3 cells showed increased levels of mitochondrial peroxides 
(Fig. 1F). Reduced glutathione (GSH) is one of the most important 
scavengers of ROS and its ratio with oxidized glutathione (GSSG) is used 
as a marker of increased ROS levels. During osteocytogenesis of 
IDG-SW3 cells, we found a progressive decrease in GSH levels and an 
increase in GSSG levels in both intact cells and isolated mitochondria 
(Fig. 1G–J). The mitochondrial content of murine primary osteoblasts 
and osteocytes was compared. Osteocytes displayed a 30–40% increase 
in the mitochondrial number per cell compared to osteoblasts (Suppl. 
Figure 2). Moreover, confocal images showed that primary osteoblast 
and osteocytes arranged their mitochondria in elongated tubules, 
forming networks that were shown to be more efficient at producing 
ATP [28]. These networks follow a similar pattern as that of ROS 
staining, suggesting that mitochondrial activity is the major source of 
ROS in these cells (Suppl. Figure 2). 
3.2. Increased NRF2 activity during osteocytogenesis 
In view of the fact that NRF2 is a major oxidative stress sensor and 
inducer of the antioxidant response, we hypothesized an increase in 
NRF2 levels and activity in response to the increase in ROS levels and 
GSSG/GSH ratio. We found a significant increase in total NRF2 protein 
levels in IDG-SW3 cells after 7 and 14 days of differentiation, whereas 
KEAP1 protein levels slightly lowered over time (Fig. 2A and B). We 
confirmed this observation of higher NRF2 activity, as the NRF2 target 
genes NAD(P)H dehydrogenase quinone 1 (Nqo1) and glutamate- 
cysteine ligase catalytic subunit (Gclc) were transcriptionally activated 
during IDG-SW3 differentiation (Fig. 2C). Similarly, transcription of 
Nfe2l2 itself was also higher throughout osteocytogenesis, whereas 
Keap1 mRNA levels remained unaltered until the 14th day when they 
were also increased (Fig. 2C). We confirmed that isolated primary mu-
rine osteocytes displayed higher expression of Nfe2l2 mRNA and NRF2 
targets Nqo1 and Gclc than primary osteoblasts, whereas Keap1 mRNA 
levels were not altered (Fig. 2D). Altogether, these findings demonstrate 
elevated NRF2 activity in osteocytes and during differentiation of IDG- 
SW3 cells and suggest that NRF2 may be required to facilitate 
osteocytogenesis. 
3.3. Nfe2l2 deletion in osteocytes causes osteopenia and impairs 
osteocyte-specific gene expression 
Whereas all previous studies reported a consistent sexual dimor-
phism, they also reported conflicting results on the effects on bone mass 
after whole-body deletion of Nfe2l2 in male mice. Moreover, 
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information about the role of NRF2 in specific bone cell types is missing. 
To determine the potential role of NRF2 in the osteocytic cell lineage, we 
first deleted its expression in mature osteoblasts and osteocytes by 
breeding Dmp1-CreERt2 mice with Nfe2l2fl/fl mice [29]. In these mice, 
Cre recombinase fused to a triple mutant form of the human estrogen 
receptor does not bind its natural ligand (17β-estradiol) under physio-
logical concentrations, but is active upon tamoxifen induction. Deletion 
was performed with low doses of tamoxifen (20 mg/kg) in 
three-week-old mice, therefore avoiding the effects of deletion at the 
embryonic or neonatal period. As previously shown using this tamoxifen 
dose, we minimized the effects of tamoxifen on bone turnover in mice 
and a robust and restricted activation of the transgene in osteocytes and 
mature osteoblasts was achieved [29–32]. Four weeks after deletion, we 
visualized bones in male and female mice in distal femurs by micro--
computed tomography scanning (μCT) and histological analysis. Dele-
tion of Nfe2l2 led to a decrease in both trabecular and cortical bone 
architecture. Dmp1-CreERt2:Nf2l2fl/fl (hereafter Dmp1/Nfe2l2-KO) male 
mice presented lower cortical bone volume (BV) associated with 
reduced cortical thickness (Cs.Th) while the bone perimeter (B.Pm) 
around the midshaft was not affected (Fig. 3A and B). Moreover, distal 
femurs in males also presented less trabecular bone volume (BV/TV) 
resulting from a significantly lower trabecular number (Tb.N) and 
thickness (Tb.Th) (Fig. 3A and B). Although lower in magnitude, 
trabecular analysis of distal femurs in Dmp1/Nfe2l2-KO females also 
showed a significant reduction in trabecular bone volume (BV/TV), 
trabecular number (Tb.N), and thickness (Tb.Th). However, reduction in 
Fig. 1. Increased OXPHOS activity and ROS 
generation are associated with osteocytic differ-
entiation. (A) Quantification of mtDNA in undif-
ferentiated IDG-SW3 after 3, 7, and 14 days of 
differentiation. Results are plotted as expression 
relative to undifferentiated IDG-SW3 (mean ± SEM; 
n = 7). (B) Analysis of the levels of mitochondrial 
complexes in undifferentiated IDG-SW3 after 3, 7, 
and 14 days of differentiation (C) Flow cytometry 
analysis of mitochondrial membrane potential using 
Mitotracker Deep Red in undifferentiated IDG-SW3 
and after 3, 7, and 14 days of differentiation. Re-
sults are plotted as expression relative to undiffer-
entiated IDG-SW3 (mean ± SEM; n = 8). (D) Flow 
cytometry analysis of total ROS stained with Cell-
ROX Deep Red in undifferentiated IDG-SW3 and 
after 3, 7, and 14 days of differentiation. Results are 
plotted as Molecules of Equivalent Fluorescein 
(mean ± SEM; n = 4). (E) Flow cytometry analysis of 
mitochondrial superoxide stained with MitoSOX Red 
in undifferentiated IDG-SW3 and after 3, 7, and 14 
days of differentiation. Results are plotted as Mole-
cules of Equivalent Fluorescein (mean ± SEM; n =
4). (F) Determination of superoxide produced in 
isolated mitochondria using Amplex Red. Results 
were normalized to citrate synthase (CS) activity. 
(mean ± SEM; n = 3). (G and H) Total GSH (G) and 
GSSG (H) in undifferentiated IDG-SW3 and after 3, 7, 
and 14 days of differentiation. Results are plotted as 
mean ± SEM (n = 5). (I, and J) GSH (I) and GSSG (J) 
levels in isolated mitochondria from undifferentiated 
IDG-SW3 and after 3, 7, and 14 days of differentia-
tion. Results were normalized to citrate synthase 
(CS) activity (mean ± SEM; n = 4 *p < 0.05, **p <
0.01, and ***p < 0.001 using Student’s t-test.   
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cortical bone parameters only reached significant differences for cortical 
thickness (Fig. 3C and D). To clarify the underlying reason for the 
osteopenic phenotype of Dmp1/Nfe2l2-KO mice, we analyzed the 
expression of osteoblast and osteocyte genes. As expected, expression of 
the NRF2 targets genes Nqo1 and Gclc were reduced in both male and 
female bones. Dmp1/Nfe2l2-KO male and female mice also displayed 
reduced expression of osteocyte genes, including Dmp1, Mepe, and Sost, 
and additional bone-cell genes, such as Runx2 or Osx (Fig. 3E). Reduced 
osteocyte gene expression occurred without significant changes in the 
density of osteocytes per bone area (N.Oc/B.Ar) (Suppl. Figure 3). 
Notably, the number of osteoclasts was significantly higher in male 
Dmp1/Nfe2l2-KO mice, whereas this increase was not significant in fe-
male mice (Suppl. Figure 2). These effects in osteoclasts took place 
without altered Rankl/Opg expression (Suppl. Figure 3). 
Given the effect of Nfe2l2 deletion in osteocytes we aimed to estab-
lish the impact of Nfe2l2 deletion in the previous steps of osteoblast 
differentiation. Osteoblast-specific Nfe2l2 mutant mice were generated 
by means of a Cre recombinase adjacent to the 2.3-Col1a1 promoter 
Nfe2l2;Col1a1-Cre (hereafter Col1a1/Nfe2l2-KO), which drives consti-
tutive expression of Cre exclusively in osteoblasts from E14 [24]. 
MicroCT analysis of distal femurs in male mice demonstrated less 
trabecular bone volume (BV/TV) and lower trabecular number (Tb.N) 
and thickness (Tb.Th), similar to Dmp1/Nfe2l2-KO mice (Fig. 4A and B). 
Surprisingly, male mice did not show major defects in cortical bone 
volume (Fig. 4A and B). Additionally, female Col1a1/Nfe2l2-KO mice 
did not show changes in either cortical or trabecular bone parameters 
(Fig. 4C and D). Expression of the NRF2 targets genes Nqo1 and Gclc 
were reduced in both male and female bones to a similar extent as that in 
Dmp1/Nfe2l2-KO mice. Col1a1/Nfe2l2-KO male and female mice also 
displayed reduced expression (about 50%) of the osteocyte genes Dmp1, 
Mepe, and Sost, but no major changes in other osteoblastic genes, such as 
Runx2 or Osx (Fig. 4E). As observed in Dmp1/Nfe2l2-KO mice, the 
number of osteocytes was unaltered and the number of osteoclasts was 
higher in male but not female Col1a1/Nfe2l2-KO mice (Suppl. Figure 4). 
In conclusion, our data demonstrate the sexually dimorphic relevant role 
of NRF2 in osteocyte gene expression and function in vivo that results in 
Fig. 2. NRF2 activity during osteocyto-
genesis. (A) Undifferentiated IDG-SW3 cells 
after 3, 7, and 14 days of differentiation 
were analyzed for NRF2 and KEAP1 protein 
expression. Tubulin levels were used as a 
protein load control. (B) NRF2 and KEAP1 
levels were quantified and normalized by 
tubulin levels. Results are plotted as mean ±
SEM (n = 3). (C) mRNA expression of Keap1, 
Nfe2l2, and target genes in undifferentiated 
IDG-SW3 after 3, 7, and 14 days of differ-
entiation. mRNA levels were quantified by 
qRT-PCR, normalized by Tbp, and plotted as 
expression relative to undifferentiated IDG- 
SW3 (mean ± SEM; n = 8) (D) mRNA 
expression of Keap1, Nfe2l2, and target 
genes in primary cultures of osteoblasts and 
osteocytes. mRNA expression was quantified 
by RT-qPCR and normalized to Tbp expres-
sion. Results are plotted as 2-ΔΔCt (mean ±
SEM; n = 6). *p < 0.05, **p < 0.01, and 
***p < 0.001 using Student’s t-test.   
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Fig. 3. Bone phenotype of mice with Nfe2l2 conditional deletion in osteocytes. (A–D) MicroCT analysis and representative images of femurs obtained from 
male (A and B) or female (C and D) Nfe2l2f/f;Dmp1-Cre-Ert2 and control (Nfe2l2f/f) mice. (E) mRNA levels in calvaria obtained from NRF2 conditional knock-out 
(Nfe2l2f/f;Dmp1-Cre-Ert2) and control (Nfe2l2f/f) mice. mRNA expression levels were measured by RT-qPCR and normalized to Tbp expression. Results are plotted as 
mean ± SEM of seven to eleven independent animals. *p < 0.05, **p < 0.01, and ***p < 0.001 using Student’s t-test. 
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Fig. 4. Bone phenotype of mice with Nfe2l2 conditional deletion in osteoblasts. (A–D) MicroCT analysis and representative images of femurs obtained from 
male (A and B) or female (C and D) Nfe2l2f/f;Col1a1-Cre and control (Nfe2l2f/f) mice (E) mRNA levels in calvaria obtained from NRF2 conditional knock-out 
(Nfe2l2f/f;Col1a1-Cre) and control (Nfe2l2f/f) mice. mRNA expression levels were measured by RT-qPCR and normalized to Tbp expression. Results are plotted 
as mean ± SEM of nine to eleven independent animals. *p < 0.05, **p < 0.01, and ***p < 0.001 using Student’s t-test. 
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lower bone mass and an increased number of osteoclasts in male mice. 
3.4. NRF2 activity regulates osteocyte-specific gene expression 
Our data suggest that some of the effects observed in vivo arise from 
the alteration of paracrine communication between distinct bone cell 
types. Therefore, to identify further cell-autonomous effects, we 
analyzed Nfe2l2 deletion in vitro on primary cultures of osteblasts and 
osteocytes after transducing them with Cre retroviruses. Expression of 
the NRF2 targets genes Nqo1 and Gclc, were strongly reduced. While 
major osteoblastic genes, such as Runx2, Osx, or Col1a1, were only 
slightly affected, osteoblasts and osteocytes displayed reduced expres-
sion of osteocytic genes, including Dmp1, Mepe, and Sost (Fig. 5A and B). 
Moreover, analysis of osteocytes overexpressing NRF2 showed inverse 
effects, including increased Nqo1 and Gclc mRNA levels and higher 
expression of the osteocytic genes Dmp1, Mepe, and Sost (Fig. 5C). 
Mechanistically, increased expression of osteocytic genes upon 
activation of NRF2 could rely on the intrinsic transcriptional effects of 
NRF2 itself or alternatively, depending on decreased ROS upon activa-
tion of the anti-oxidative machinery. We tested this hypothesis by 
treatment of osteocytes deficient in Nfe2l2 with 1 mM N-acetyl-cysteine 
(NAC). Antioxidant treatment slightly reduced Nqo1 and Gclc expression 
levels in control osteocytes, whereas osteocytes deficient in Nfe2l2 were 
refractory to changes upon NAC addition (Suppl. Figure 5). Either 
treatment of NAC or deficiency of Nfe2l2 had no major effects on Runx2 
or Col1a1 expression, and only slightly decreased Osx mRNA levels in 
Nfe2l2 deficient osteocytes (Suppl. Figure 5). As shown above, Nfe2l2 
deficiency reduced the levels of Dmp1, Mepe, and Sost. More impor-
tantly, the antioxidant effects of NAC did not alter expression of Dmp1 in 
control cells, or after Nfe2l2 deletion, but reduced Mepe and Sost mRNA 
expression independent of the Nfe2l2 status (Suppl. Figure 5). NAC is not 
only an antioxidant but also a cysteine source that can change redox 
thiol signaling independently of ROS. Therefore, we also analyzed 
expression of osteocytic genes after addition of the non-thiol antioxi-
dants Trolox and MitoQ. Trolox is an analog of vitamin E also used to 
reduce oxidative stress, whereas Mito Q is a mitochondria-targeted 
antioxidant designed to protect against oxidative damage. Treatment 
of osteocytes with this non-thiol antioxidants yielded similar results 
where osteocytes deficient in Nfe2l2 were refractory to changes upon 
antioxidant addition (Suppl. Figure 6). 
Several drugs with the ability to activate NRF2 have been developed. 
Among them, dimethyl fumarate (DMF) was shown to activate NRF2 
and an antioxidant response and it has been approved for the treatment 
of multiple sclerosis or psoriasis [33]. To further confirm whether the 
expression of osteocytic genes was modulated by NRF2, we treated os-
teocytes deficient for Nfe2l2 with 5 μM DMF. This dose is far below the 
maximum serum concentration of DMF when clinically administrated 
(www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf). 
DMF treatment increased Nqo1 and Gclc expression levels in control 
osteocytes, whereas in osteocytes deficient for Nfe2l2, these responses 
were blunted (Suppl. Figure 5). DMF had no major effects on Runx2, or 
Col1a1 expression but strongly induced expression of Dmp1, Mepe, and 
Sost mRNA expression in control cells. These responses were severely 
reduced in Nfe2l-deficient osteocytes (Suppl. Figure 5). Altogether, the 
data suggest that NRF2 activity led to transcriptional activation of these 
genes. 
Genomic analysis indicated that Dmp1, Mepe, and additional SIB-
LING (Small Integrin-Binding LIgand, N-linked glycoproteins) family 
members, such as Dspp, Ibsp, or Spp1, share the same topologically 
associated domain (TAD) in human chromosome 4 (Fig. 6A). TADs play 
a critical role, favoring the contact of shared regulatory elements and 
preventing undesired interactions with neighboring TADs [34]. Bio-
informatic analysis of whole-genome NRF2-ChipSeq data 
(GSE113497G) showed that this TAD is highly enriched for binding 
NRF2 (Fig. 6B) and correlates with the presence of the known NRF2 
target Abcg2 in the close vicinity. We confirmed binding of NRF2 to the 
regulatory region of Dmp1 by ChIP assays in primary osteocytes after 
DMF activation (Fig. 6C). Similarly, whole-genome NRF2-ChipSeq data 
(GSE113497G) showed strong NRF2 binding in the distal enhancer 
located at 3′of the Sost gene (Fig. 6E). This distal enhancer has been 
shown to be sufficient for osteocyte specific expression of Sost and its 
deletion to be causative of Van Buchem disease [35,36]. We also 
confirmed binding of NRF2 to the regulatory region of Sost by ChIP 
assays in primary osteocytes after DMF activation (Fig. 6F). In conclu-
sion, the data suggests that NRF2 activated expression of Dmp1, Mepe, 
and Sost through direct binding to their regulatory regions. 
Fig. 5. Activation of Nrf2 induce osteocyte-specific gene expression. (A 
and B) mRNA expression levels of osteoblastic and osteocytic genes in primary 
osteoblasts (A) (n = 9) and primary osteocytes (B) (n = 9) wild type and 
knockout for NRF2. (C) mRNA expression in primary osteocytes infected with 
NRF2 expression vectors (n = 6). mRNA expression levels were measured by 
RT-qPCR and normalized to Tbp expression. Results were plotted as expression 
relative to cells infected with GFP vector (mean ± SEM of six to eight inde-
pendent experiments). *p < 0.05, **p < 0.01, and ***p < 0.001 using Student’s 
t-test. 
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3.5. DMF treatment preserves bone mass and osteocytic gene expression in 
ovariectomy-induced osteoporosis 
A number of pathological conditions are alleviated by NRF2 activa-
tion, including chronic kidney disease, multiple sclerosis, hepatotoxici-
ty, or rheumatoid arthritis [16]. However, information about potential 
beneficial effects of pharmacological activation of NRF2 in bone pa-
thologies is scarce [37,38]. We analyzed the effects of DMF in osteopenia 
induced by ovariectomy (OVX), an established model to induce osteo-
porotic bone loss. Ovariectomized mice were treated with 100 mg/kg of 
DMF for 8 weeks. MicroCT analysis indicated that cortical bone pa-
rameters were not significantly modified by either ovariectomy or DMF 
treatment (Fig. 7A and B). However, ovariectomized mice displayed 
decreased trabecular bone mass, mostly due to a reduced number of 
trabeculae. More importantly, treatment with DMF restored the 
trabecular bone mass and increased the number of trabeculae and their 
thickness in ovariectomized mice (Fig. 7A and B). Gene expression 
analysis indicated that ovariectomy led to decreased levels of Nfe2l2, 
whereas DMF treatment restored the levels of Nfe2l2 and increased the 
levels of its target Nqo1 (Suppl. Figure 7). Ovariectomized mice also had 
reduced expression of Dmp1, Osx, and Sost, whereas DMF treatment was 
able to rescue their gene expression in bone (Suppl Figure 7). Histo-
morphometric measurements showed that the number of osteoclasts was 
significantly higher in OVX mice, whereas this increase was reduced 
when these mice were treated with DMF (Suppl. Figure 7). These results 
demonstrate that DMF treatment restored the expression of the osteo-
cytic genes Dmp1, Osx, and Sost and was effective in rescuing the 
osteopenic phenotype after ovariectomy. 
4. Discussion 
In this study, we identified that increased mitochondrial content led 
to increased levels of ROS during the transition from osteoblasts to os-
teocytes. As a major sensor of oxidative stress, the transcription factor 
NRF2 becomes activated during osteocytogenesis and directly trans-
activates a number of osteocyte-specific gens such as Dmp1, Mepe, and 
Sost. Furthermore, we found that mice deficient for NRF2 in osteocytes 
and mature osteoblasts were osteopenic with significant sexual 
Fig. 6. Osteocytic genes are orga-
nized in TADs regulated by NRF2 (A 
and D) Topological domain and looping 
structure indicated by Hi-C data from 
Dixon et al. (2015) in MSC. The sche-
matic shows TAD (red-shaded triangle) 
containing the SIBLING family of pro-
teins (A) and Sost (D). (B and E) ChIP-seq 
data showing NRF2 binding sites in 
A549 cells (data obtained from 
GSE113497), as well as active promoter/ 
enhancer associated histone mark 
H3K27ac, gene body associated histone 
mark H3K36me3 and promoter associ-
ated histone mark H3K4me3 obtained 
from human osteoblast epigenome. (C 
and F). Chromatin immunoprecipitation 
from osteocytes cultured in the presence 
or absence of 5 μM DMF for 48 h. Results 
were normalized to input chromatin and 
plotted relative to untreated osteocytes 
(mean ± SEM; n = 5). *P < 0.05, **P <
0.01, and ***P < 0.001 using Student’s 
t-test. (For interpretation of the refer-
ences to colour in this figure legend, the 
reader is referred to the Web version of 
this article.)   
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dimorphism. Finally, treatment of ovariectomized mice with the NRF2 
activator DMF restored their bone loss phenotype. Our comprehensive 
analysis in cells and genetic mouse models strongly support a relevant 
role for NRF2 in osteocytes for the maintenance of bone homeostasis. 
In recent years, several studies have demonstrated that the meta-
bolism of osteocytes optimize energy production to fulfill functional 
demands in a nutrient-restricted environment [39]. Our data showed a 
higher mitochondrial mass and function during the transition of osteo-
blasts into osteocytes. Accordingly, osteocytes in vivo contain numerous 
mitochondria to maintain their energy status [40,41]. As expected, since 
ROS mainly arise as byproducts of aerobic mitochondrial complexes I, 
and III, ROS levels increase during the transition from osteoblast to 
osteocyte. Unregulated accumulation of ROS has been shown to be a 
major contributor to aging and several diseases that include osteoporosis 
and bone diseases [12,14]. In contrast, we found that ROS at lower, 
non-toxic levels could actually contribute to osteocyte specification, as 
shown for other mesenchymal stem cell differentiation processes [13, 
42]. This link between ROS and cellular specification was already 
established for neurogenesis, astrocytogenesis, hepatic differentiation, 
and erythropoiesis [43–46]. Consistent with its role as a regulator of 
oxidative stress, we found a correlation between NRF2 activity, mito-
chondrial content, and ROS levels during osteocytogenesis. Moreover, 
NRF2 activity increases have been associated with increased mito-
chondrial function as a feed-forward loop [47]. 
To address the unresolved issues of the role of NRF2 in specific bone 
cells in vivo, we found evidence that NRF2 activity has an indispensable 
role in the maintenance of bone homeostasis, both in the cortical and 
trabecular compartments. Previous studies with global deletion of NRF2 
have shown sexual dimorphism in the skeletal phenotype [17–20,22]. 
Our data confirm this sexual dimorphism, with more profound effects of 
NRF2 deletion on bone mass in male mice. Interestingly, 
Dmp1/Nfe2l2-KO mice of both sexes display severe osteopenia, while 
Fig. 7. Dimethylfumarate (DMF) reduces bone loss induced by ovariectomy. (A) MicroCT analysis of femurs obtained from ovariectomized (OVX) and sham 
operated (SHAM) mice treated with 100 mg/kg of dimethylfumarate (DMF) or vehicle. (B) Representative images of cortical and trabecular section of femurs ob-
tained from OVX and SHAM mice treated with 100 mg/kg of DMF or vehicle. Results are plotted as mean ± SEM of seven to eleven independent animals. *p < 0.05, 
** or ##p < 0.01, *** or ###p < 0.001 using Student’s t-test. * refer to statistics performed against SHAM mice treated with vehicle. Similarly, # refers to sig-
nificance between OVF mice treated with vehicle or DMF. 
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Col1a1/Nfe2l2-KO mice only exhibit subtle osteopenia in males and 
non-significant changes in the female’s skeleton. We observed that levels 
of CRE expression (Suppl. Figure 8), deletion of Nfe2l2, and expression 
of its target genes Nqo1 and Gclc were modified similarly in both models, 
arguing against different deleting efficiency. It is possible that deletion 
in the late embryonic and neonatal period (in Col1a1/Nfe2l2-KO), 
compared to deletion at postnatal P21-28 (in Dmp1/Nfe2l2-KO), could 
reprogram compensatory mechanisms in the former to keep bone for-
mation and turnover. For instance, whereas Runx2 and Osx expression 
was significantly diminished in Dmp1/Nfe2l2-KO mice, it remains un-
altered in Col1a1/Nfe2l2-KO of both sexes. Alternatively, it is possible 
that Nfe2l2 deletion in osteoblasts (Col1a1/Nfe2l2) or osteocytes 
(Dmp1/Nfe2l2) could somehow differentially modify their function 
and/or paracrine crosstalk to osteoclasts. More detailed studies are 
required to further explore these possibilities. 
Our results also provide additional information about sexual 
dimorphism, observed previously after global Nfe2l2 deletion [17–20, 
22]. Although in our study deletion was performed only in the osteo-
blast/osteocyte lineages, dimorphic effects in bone parameters correlate 
with differential changes in osteoclast numbers. Interaction between 
NRF2 activation and signaling downstream of the sex steroid receptors 
could contribute to sex-specific differential regulation. For instance, 
deletion of estrogen receptors (ERα or β) differentially affects bone pa-
rameters in female and male mice and NRF2 displays transcriptional 
cooperation with ERs [48,49]. Similarly, androgen receptor (AR) func-
tion in osteocytes is required for proper bone homeostasis and NRF2 
modifies AR-mediated transactivation [50,51]. Supporting this hy-
pothesis, it has been shown that dissimilar expression of cytoprotective 
genes, Rankl/Opg ratio, or osteoclast numbers correlate with different 
effects of Nfe2l2 in bone maintenance, depending on sex [17,18]. NRF2 
has been shown to negatively regulate the expression of cytokines that 
induce osteoclastogenesis, such as IL-1α, IL1β, IL6, TNFα, or RANKL 
[52–54]. Therefore, it is plausible to suggest that deletion of Nfe2l2 in 
osteocytes and mature osteoblasts would increase paracrine osteoclas-
togenic signaling. 
Independent of the in vivo deletion model, sex, or in vitro genetic and 
pharmacological approaches, NRF2 activity induced transcriptional 
activation of a topologically associated domain (TAD), containing the 
SIBLING family of extracellular proteins. The SIBLING protein family is a 
structurally and phylogenetically homogeneous group that comprises 
Dspp, Dmp1, Mepe, Osteopontin Spp1, and Ibsp, located on human 
chromosome 4, which shows specific expression in bone cell types [55, 
56]. Sequencing data suggest that the SIBLING gene group appeared 
along with generation of the bony skeleton in the vertebrate lineage, 
highlighting their importance for bone tissue [57–60]. SIBLING proteins 
are required for proper bone mineralization, as its defects led to osteo-
porosis and shared significant levels of functional redundancy [61,62]. 
Moreover, SIBLING proteins have been shown to inhibit osteoclast dif-
ferentiation [61]. Whole-genome Chip-Seq assays and our Chip assays in 
osteocytes showed that this TAD, which also contains the canonical 
NRF2-activated gene Abcg2, bound NRF2, strongly suggesting that NRF2 
activity has a key role in the regulation of SIBLING proteins in osteo-
blasts and osteocytes. Similarly, NRF2 bound to the 3′ region of the Sost 
gene in whole-genome Chip-Seq assays and our Chip assays. This region 
has been shown to be essential for osteocyte-specific expression and is 
responsible for Van Buchem disease [35]. Altogether, our results 
demonstrate the important role of NRF2 activity in the regulation of a 
number of relevant osteocyte-specific genes in vitro and in vivo. 
Given these results we hypothesized that activation of NRF2 could 
become effective for bone pathologies. DMF (Tecfidera) was approved 
by the FDA and EMA after showing clinical effectiveness in patients with 
multiple sclerosis (www.accessdata.fda.gov/drugsatfda_docs/label/20 
14/204063s003s008s010lbl.pdf). DMF has a good tolerability and 
safety profile in humans and the most common adverse events were 
flushing and gastrointestinal events, which were of mild or moderate 
severity and appeared to be largely manageable [63]. Our data 
demonstrated that treatment with DMF prevented the deleterious effects 
of ovariectomy in the skeleton. Bone mass and architecture was mostly 
protected in the trabecular compartment. In addition, we found a 
decreased number of osteoclasts in DMF treated mice. Treatment with 
DMF also restored the expression of Dmp1, Osx, and Sost in ovariecto-
mized mice, therefore improving osteocyte function and potential 
inhibitory effects on osteoclasts. However, we cannot exclude a direct 
effect of DMF on the reduction of recruitment and activation of osteo-
clasts through attenuation of ROS signaling as previously reported [37] 
or effects mediated by additional signaling pathways inhibited by DMF, 
such as NF-κB [64]. Therefore, further studies should be performed to 
optimize dosing and to fully understand the bone protecting mecha-
nisms of DMF. 
5. Conclusions 
We report that increased mitochondrial biogenesis raised ROS levels 
and NRF2 activity during osteocytogenesis. NRF2 activity promoted 
osteocytic specification through transcriptional activation of osteocyte- 
specific genes. Furthermore, conditional ablation of Nfe2l2 in osteocytes 
or osteoblasts are evidence of its fundamental role in bone homeostasis. 
Finally, our results showed that treatment with the NRF2 activator 
dimethyl fumarate (DMF) might be beneficial for osteopenic bone pa-
thologies. Altogether, we have uncovered the central role of NRF2 in 
bone homeostasis and the establishment of a transcriptional program 
leading to osteocyte specification. 
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